Patent · US Active

Compound as porcupine inhibitor and use thereof

US12365686B2 · kind B2 · utility

0Cited by

0References

16Claims

0Family size

Assignee

JIANGSU KANION PHARMACEUTICAL CO., LTD · CN

Inventors

Xiongbin XU · Shanghai, CN
Yi Chen · Shanghai, CN
Cailin WANG · Shanghai, CN
Ru Feng · Shanghai, CN
Wen Jiang · Shanghai, CN
Lingyun WU · Shanghai, CN
Jian Li · Shanghai, CN
Shuhui CHEN · Shanghai, CN

Key dates

Filing date	Jul 8, 2020
Grant date	Jul 22, 2025
Priority date	—
Expiry date	Oct 9, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D403/12
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed is a class of porcupine inhibitors, specifically a compound as represented by formula (I), and a pharmaceutically acceptable salt or an isomer thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.